Abstract
Background Irrational use of this drug leads to emergence of resistant bacteria and also leads to infections that are worse than the original diagnosed ones. Important concern is the uncertainty of administered antibiotics about whether the quality of a generic medicine is equal to brand name drug; if both brand/generic are bioequivalent, then antibiotic selection should be based on the cost of therapy. Methods The efficacy of seven ceftriaxone brands available at Ambo, Oromia Regional State, Ethiopia, was evaluated by microwell plate diffusion technique against four different bacteria. Results All brands of two concentrations were showed sufficient inhibitory activity against four microorganisms, so they should all be considered as bioequivalence. Among all brands tested, B6 showed higher activity against Escherichia coli American Type Culture Collection (ATCC) 10536, Staphylococcus aureus ATCC 29737 and Pseudomonas aeruginosa ATCC 25619, and B1 showed higher activity against Salmonella typhi ATCC 06775. Interestingly, the concentration C2 (50 μg/ml) of B1–B7 showed equivalent zone of inhibition to that of the standard. Conclusion We conclude that performance of tested ceftriaxone injectable products were equivalent to the standard. We recommend that the physicians may select the ceftriaxone brand which is low cost in order to reduce the cost of treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Pharmaceutical Health Services Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.